StableX Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that StableX Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $4.58M | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $6.08M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $4.29M | Apr 12, 2019 |
| FY2017 | Apr 30, 2017 | $16.74M | Jul 21, 2017 |
| FY2017 | Apr 30, 2016 | $14.56M | Jul 21, 2017 |
| FY2016 | Apr 30, 2015 | $24.42M | Jul 28, 2016 |
| FY2015 | Apr 30, 2014 | $15.75M | Jul 29, 2015 |
| FY2014 | Apr 30, 2013 | $24.77M | Jul 30, 2014 |
| FY2013 | Apr 30, 2012 | $65.46M | Jul 29, 2013 |
| FY2012 | Apr 30, 2011 | $84.09M | Jul 30, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $63.8K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $498.9K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.99M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.68M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.60M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $890.2K | Mar 31, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($956.2K) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($6.59M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($4.64M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.05M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.09M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($166.5K) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $198.3K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.79M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($257.9K) | Apr 12, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.09M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.76M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($34.16M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($22.94M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($33.08M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($10.76M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($8.66M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($18.75M) | Mar 30, 2020 |
| FY2018 | Sep 30, 2018 | ($11.80M) | Apr 12, 2019 |
| FY2018 | Jun 30, 2018 | ($8.47M) | Apr 12, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.46M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($19.38M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($28.16M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($23.28M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($33.13M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($10.11M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($8.49M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($2.23M) | Mar 30, 2020 |
| FY2018 | Sep 30, 2018 | ($10.72M) | Apr 12, 2019 |
| FY2018 | Jun 30, 2018 | ($7.39M) | Apr 12, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.39M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.49M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $7.42M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.85M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $11.45M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.92M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $714.3K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $322.3K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $90.1K | Apr 12, 2019 |
| FY2014 | Apr 30, 2014 | $269.0K | Jul 30, 2014 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $2.48M | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $2.23M | Mar 30, 2020 |
| FY2018 | Sep 30, 2018 | $10.87M | Apr 12, 2019 |
| FY2018 | Jun 30, 2018 | $7.55M | Apr 12, 2019 |
| FY2018 | Mar 31, 2018 | $3.51M | Apr 12, 2019 |
| FY2018 | Dec 31, 2017 | $5.75M | Apr 12, 2019 |
| FY2017 | Apr 30, 2017 | $6.27M | Jul 21, 2017 |
| FY2017 | Apr 30, 2016 | $6.95M | Jul 21, 2017 |
| FY2016 | Apr 30, 2015 | $4.87M | Jul 28, 2016 |
| FY2015 | Apr 30, 2014 | $5.07M | Jul 29, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.70M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($13.32M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($26.18M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($18.73M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($26.63M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($10.02M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($4.10M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($10.57M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($4.22M) | Apr 12, 2019 |
| FY2017 | Apr 30, 2017 | ($1.37M) | Jul 21, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $199.3K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $2.14M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.59M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $538.0K | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $504.3K | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $469.8K | Mar 31, 2021 |
| FY2018 | Dec 31, 2018 | ($43.1K) | Apr 12, 2019 |
| FY2018 | Dec 31, 2017 | ($6.6K) | Apr 12, 2019 |
| FY2017 | Apr 30, 2017 | $77.3K | Jul 21, 2017 |
| FY2017 | Apr 30, 2016 | $139.6K | Jul 21, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.41M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $21.74M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $52.86M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $54.99M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $78.13M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $41.96M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $2.78M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.63M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.21M | Apr 12, 2019 |
| FY2017 | Apr 30, 2017 | $7.15M | Jul 21, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.70M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $9.47M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $27.53M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.93M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.70M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $2.60M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $2.71M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.59M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $5.70M | Apr 12, 2019 |
| FY2017 | Apr 30, 2017 | $4.07M | Jul 21, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.71M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.68M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $14.14M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $52.06M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $73.42M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $39.36M | Mar 23, 2023 |
| FY2021 | Dec 31, 2019 | $68.9K | Mar 23, 2022 |
| FY2020 | Dec 31, 2018 | $108.4K | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | ($4.49M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $83.3K | Apr 12, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $3.41M | Mar 30, 2020 |
| FY2018 | Dec 31, 2018 | $3.41M | Apr 12, 2019 |
| FY2013 | Apr 30, 2013 | $0 | Jul 29, 2013 |
| FY2013 | Apr 30, 2012 | $1.93M | Jul 29, 2013 |
| FY2013 | Apr 30, 2011 | $2.04M | Jul 29, 2013 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($138.17M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($117.09M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($115.33M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($81.17M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($58.23M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($25.15M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($13.96M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($29.75M) | Mar 30, 2020 |
| FY2018 | Sep 30, 2018 | ($22.74M) | Apr 12, 2019 |
| FY2018 | Jun 30, 2018 | ($18.39M) | Apr 12, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.98M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $16.04M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $33.44M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $39.10M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $69.16M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $36.54M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $641.8K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.89M | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $0 | Mar 30, 2020 |
| FY2017 | Apr 30, 2017 | $1.66M | Jul 21, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $21.6K | Mar 31, 2021 |
| FY2020 | Dec 31, 2019 | $1.32M | Mar 31, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (32) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (32) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 23, 2023 |
| FY2019 | Dec 31, 2019 | (1) | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | (14) | Mar 30, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (32) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (32) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (8) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Apr 1, 2024 |
| FY2019 | Dec 31, 2019 | (1) | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | (14) | Mar 30, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.46M | Mar 30, 2026 |
| FY2025 | Jun 25, 2025 | 16 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 533,842 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 4.91M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 4.66M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 36.87M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 27.09M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | 3.95M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 1.63M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 9.80M | Apr 12, 2019 |